---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-25-000050"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:47:06.849216+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q1 product rev $469M (+28% YoY); AMVUTTRA approved for ATTR-CM; guides FY25 $2.05-2.25B

## Summary
- Q1 total revenues $594M, up 20% YoY; GAAP operating income $18M vs loss of $43M in Q1 2024.
- Q1 global net product revenues $469M, 28% growth YoY; hATTR-PN franchise grew 36%.
- AMVUTTRA (vutrisiran) received FDA approval for ATTR-CM; launch underway with early progress.
- Qfitlia (fitusiran) approved by FDA for hemophilia A/B, sixth Alnylam-discovered RNAi therapeutic.
- Reiterated FY2025 combined net product revenue guidance of $2.05B-$2.25B.

## SEC filing metadata
- accession: 0001178670-25-000050
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000050/0001178670-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000050/alny-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-25-000050
- JSON: https://secwatch.observer/filing/0001178670-25-000050.json
- Plain text: https://secwatch.observer/filing/0001178670-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.